Company Info
| Phone: | (312) 416-8592 |
| Year Established: | 2018 |
| Ticker: | MAIA |
| Exchange: | NYSE |
Contacts
| Primary: | Vlad Vitoc, MD, MBA CEO |
| Other: | Jeffrey C. Himmelreich Head of Finance Sergei M. Gryaznov, PhD CSO |
Company Description
MAIA Biotechnology is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.
